Customize your JAMA Network experience by selecting one or more topics from the list below.
Koh and coauthors evaluate whether there are any differences in treatment outcomes between combination therapy of intravitreal ranibizumab plus verteporfin photodynamic therapy compared with ranibizumab monotherapy for polypoidal choroidal vasculopathy in a multicenter randomized clinical trial. Among 322 Asian participants, treatment of polypoidal choroidal vasculopathy with ranibizumab plus verteporfin photodynamic therapy resulted in greater visual acuity improvement with monotherapy and greater likelihood of resolution of polypoidal lesions on indocyanine green angiography using fewer ranibizumab injections. These data suggest ranibizumab plus verteporfin photodynamic therapy should be considered as a viable treatment strategy for eyes with polypoidal choroidal vasculopathy.
Highlights. JAMA Ophthalmol. 2017;135(11):1135. doi:https://doi.org/10.1001/jamaophthalmol.2016.3762
Create a personal account or sign in to: